MoonLake Immunotherapeutics (MLTX) Financials

MoonLake Immunotherapeutics (NASDAQ: MLTX) remains a clinical-stage biotech with no product revenue, so the story is still centered on cash runway, operating losses, and balance sheet strength rather than sales growth.

What stands out most in the latest quarter (Q1 2026) is that MoonLake still had a very large cash balance, but it also continued to burn cash at a heavy rate. The company ended the quarter with $357.9 million in cash and short-term investments combined, down from $380.5 million at year-end 2025 and well below the $425.1 million combined balance a year earlier. At the same time, Q1 2026 operating cash burn was $66.3 million, which is substantial for a company with no revenue.

Key positives

• Strong liquidity remains intact: MoonLake ended Q1 2026 with $298.5 million in cash and equivalents and $59.4 million in short-term investments, giving it a sizable near-term funding cushion.
• Balance sheet debt is manageable relative to cash: The company reported $99.0 million of long-term debt against $357.9 million of combined cash and short-term investments.
• Equity base is still healthy: Total common equity was $254.0 million at the end of Q1 2026, indicating the company is still well-capitalized on an accounting basis.
• Financing activity helped offset losses: Q1 2026 included $24.5 million of debt issuance and $6.0 million of common equity issuance, which supported the cash position.
• Other income partially offset operating losses: MoonLake generated $3.2 million of other income in Q1 2026, helping reduce the pretax loss modestly.

Neutral items

• No revenue yet: Total revenue was still $0 in Q1 2026, so investors are waiting for clinical or commercial catalysts.
• R&D spending remains high: Research and development expense was $54.5 million in Q1 2026, consistent with a company advancing drug development but still pressuring earnings.
• Share count remains elevated versus early 2024: Weighted average diluted shares were 71.3 million in Q1 2026, up from the low-60 million range seen in much of 2024-2025, which can dilute future per-share value.

Key negatives

• Operating losses remain very large: MoonLake posted an operating loss of $70.0 million in Q1 2026 and a net loss of $69.7 million.
• Cash burn is still significant: Operating cash flow was negative $66.3 million in Q1 2026, pointing to a continued need for external funding over time.
• Cash and investments have declined: Combined cash and short-term investments fell from $425.1 million in Q1 2025 to $357.9 million in Q1 2026.
• Interest expense is increasing: Interest expense rose to $2.27 million in Q1 2026 from $2.00 million in Q4 2025 and was near $2.0 million in prior quarters, adding to losses.
• Liabilities are rising: Total liabilities increased to $146.4 million in Q1 2026 from $102.2 million in Q2 2025, driven in part by higher debt and current liabilities.

Longer-term trend

Over the last four years, MoonLake has followed the classic biotech pattern: no revenue, recurring losses, and heavy dependence on financing. Operating expenses have generally trended higher as the company scaled its development efforts, while cash balances have swung based on financing and investment activity. The company’s cash position was especially strong in 2024 and early 2025, but it has since come down as clinical spending and quarterly losses accumulated.

Bottom line: MoonLake has enough cash for now, but the business still burns a lot of money and has not yet generated sales. For retail investors, the key question is whether the company can create meaningful clinical value before its cash runway gets stretched too far.